Clinical Psychopharmacology, every concept, explained free
Every Clinical Psychopharmacology concept for MRCPsych Prep, explained free, clear mental models, exam recognition, and the look-alikes that trip people up. Your daily session is free, always.
- Switching antidepressants
- Anti-dementia drug mechanisms (cholinesterase inhibitors and memantine)
- Antidepressants in pregnancy
- Lithium teratogenicity
- Pharmacodynamic terms
- Lithium toxicity and monitoring
- Substance pharmacology (stimulants)
- Teratogenicity in pregnancy
- Drug half-lives
- Prodrugs and active metabolites
- Transcranial magnetic stimulation (TMS)
- Pregabalin and gabapentin
- Tolerance and cross-tolerance
- Congenital malformations associated with valproate in pregnancy
- MAOI dietary interactions (tyramine)
- Therapeutic drug monitoring
- ECT mechanism of action
- Eating disorder epidemiology
- Orexin receptor antagonists
- Vagus nerve stimulation (VNS)
- Antipsychotic hyperprolactinaemia
- Tardive dyskinesia
- Flumazenil
- Hyperprolactinaemia management
- Antipsychotic-induced metabolic syndrome
- Plasma protein binding
- Alcohol pharmacokinetics
- Alpha-1 antagonism effects
- Neuroleptic malignant syndrome
- Clozapine safety
- Clonidine and alpha-2 adrenergic agonists
- Neurosurgery for mental disorder (psychosurgery)
- Psychotropic drug interactions (warfarin, St John's wort)
- Electroconvulsive therapy (ECT)
- Serotonin syndrome versus NMS
- Melatonin and ramelteon
- Antipsychotic receptor pharmacology
- Z-drugs / GABA
- Clozapine seizure risk
- Anticonvulsant mood stabilisers (valproate / carbamazepine / lamotrigine)
- Aripiprazole partial D2 agonism
- Drug mechanisms (MOA)
- Lithium side effects
- Disulfiram reaction
- Beta-blockers in psychiatry
- Glutamate modulators (NMDA)
- Serotonin syndrome
- Acetylator status and metabolism
- Buspirone
- Naltrexone and acamprosate
- Agomelatine mechanism
- Postural (orthostatic) hypotension: definition and criteria
- Pharmacokinetic order (first-order vs steady state)
- Seizure threshold and drugs
- Newer antipsychotic mechanisms (cariprazine, lurasidone, brexpiprazole)
- Smoking and drug metabolism
- Pellagra (niacin/B3 deficiency)
- Drug selection (clinical)
- Zero-order kinetics
- Mood stabilisers in pregnancy
- Bupropion mechanism
- Antidepressant mechanisms
- Area under the curve
- Amantadine
- Depot antipsychotic kinetics
- Sildenafil mechanism
- CATIE trial
- Atypical antipsychotic receptor profile
- Herbal psychotropics: St John's Wort and Kava
- Light therapy for seasonal affective disorder
- Safe sedatives in hepatic impairment (LOT rule)
- Ketamine and esketamine
- SSRI bleeding risk
- Varenicline (nicotinic partial agonist)
- Antidepressant discontinuation
- Benzodiazepine mechanism
- Beta-blocker contraindications
- Mood stabiliser choice in renal impairment
- Extrapyramidal side effects (acute dystonia and drug-induced parkinsonism)
- Antipsychotic chemical classes
- ADHD pharmacology
- Opioid pharmacology
- Drug interactions (cytochrome P450)
- Drug-specific side effects
- Lithium interactions and toxicity triggers
- Akathisia
- QTc prolongation with psychotropics
- QT prolongation from drug interactions
- Deep brain stimulation (DBS)
Free at mrcpsych.co.uk · An independent study tool · not affiliated with the Royal College of Psychiatrists